FDA Approved Autoinjector for Multiple Sclerosis Patients
For multiple sclerosis patients who use Betaseron, the interferon beta-1b prescription drug designed to reduce relapses in individuals with relapsing-remitting MS, a new delivery system will be available soon in the United States. The Food and Drug Administration (FDA) has approved Bayer’s BetaConnect, the first electronic autoinjector for treating RRMS.
The BetaConnect, which is already being used in Europe, will be made available in early 2016 exclusively to individuals in the US who take Betaseron. The rechargeable, handheld autoinjector provides users with several features that can make dosing easier and safer.
For example, users will be able to customize the injection speed and depth before delivering the dose at the touch of a button. The speed options are slow, medium, or fast, and the depth options are 8, 10, or 12 mm. Bayer urges patients to talk to their healthcare provider before they make any changes to these features.
Once the injection is given, patients will know it is complete because the autoinjector has a visual and audio end-of-dose indictor. An additional feature, which is optional, is a reminder function that lets patients know when their next injection should be taken.
The Betaseron website also offers a registration form for users of this drug to apply for their free BetaConnect now. A feature called BETAPLUS, which includes 24/7 assistance from a BETA nurse, is also offered.
Betaseron is prescribed for individuals with relapsing-remitting multiple sclerosis to help reduce the number of relapses. It can be used by individuals who have had their initial symptoms of the disease and have a magnetic resonance imaging (MRI) consistent with a diagnosis of MS.
Note: The information provided in this article is offered as a service only and in no way represents my approval or disapproval of the products mentioned.